MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical …
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - Clinical Cancer …, 2019 - AACR
Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma
G Brigliadori, F Foca, M Dall'Agata, C Rengucci… - Journal of neuro …, 2016 - Springer
Despite advances in the treatment of glioblastoma (GBM), median survival is 12–15 months.
O 6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is …
O 6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is …
Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
Background The current standard of care for the management of patients with newly
diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy …
diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy …
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study
BM Costa, C Caeiro, I Guimarães… - Oncology …, 2010 - spandidos-publications.com
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The
identification of novel molecular prognostic markers of GBM has recently been an area of …
identification of novel molecular prognostic markers of GBM has recently been an area of …
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT …
Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly
diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA …
diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA …
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter—still a dilemma?
ME Hegi, R Stupp - Neuro-oncology, 2015 - academic.oup.com
Ten years ago we established O-6-methylguanine-DNA methyltransferase (MGMT) gene
promoter methylation as the first predictive marker in neuro-oncology, and the strongest …
promoter methylation as the first predictive marker in neuro-oncology, and the strongest …
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study
PURPOSE: Recently, cells deficient in O6-methylguanine–DNA methyltransferase (MGMT)
were found to show increased sensitivity to temozolomide (TMZ). We evaluated whether …
were found to show increased sensitivity to temozolomide (TMZ). We evaluated whether …
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a …
Background The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT)
causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high …
causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high …
[HTML][HTML] Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
J Dunn, A Baborie, F Alam, K Joyce, M Moxham… - British journal of …, 2009 - nature.com
Background: Epigenetic silencing of O 6-methylguanine-DNA-methyltransferase (MGMT) by
promoter methylation is associated with improved survival in glioblastomas treated with …
promoter methylation is associated with improved survival in glioblastomas treated with …
O 6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients
S Spiegl-Kreinecker, C Pirker, M Filipits… - Neuro …, 2010 - academic.oup.com
Abstract O 6-Methylguanine DNA methyltransferase (MGMT) is implicated as a major
predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of …
predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of …
相关搜索
- glioblastoma patients mgmt promoter
- pooled analysis safety margin
- extent of mgmt promoter methylation
- mgmt gene promoter methylation
- meta analysis mgmt promoter
- still a dilemma mgmt promoter
- temozolomide and radiotherapy outcome in glioblastomas
- progressive glioblastoma temozolomide rechallenge
- overall survival people with glioblastoma
- glioblastoma patients safety margin
- glioblastoma patients pooled analysis
- glioblastoma patients temozolomide therapy
- glioblastoma patients still a dilemma
- glioblastoma patients tumor cells
- glioblastoma patients prognostic value
- meta analysis overall survival